Clinical Trials in Denver

Showing 7441-7460 of 18,161 trials

Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)

NCT04142619

This is a Phase I, FIH, open-label, dose escalation study evaluating Safety and Efficacy of UCART targeting CS1 in patients with Relapsed or Refractory Multiple Myeloma (MM). The purpose of this study is to evaluate the safety and clinical activity of UCARTCS1A and to determine the Maximum Tolerated Dose (MTD).

Relapsed/Refractory Multiple Myeloma

Cellectis S.A.11 participantsStarted Nov 2019

San Francisco, California, United States • Denver, Colorado, United States • Atlanta, Georgia, United States +5 more locations

COMPLETEDPhase 3< 1 mile

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

NCT02760433

The purpose of this study was to determine how effective and safe the study drug Olokizumab was in patients with Rheumatoid Arthritis (RA) who had been already receiving, but not fully responding to treatment with an existing medication called a tumour necrosis factor alpha inhibitor The primary objective of this study was to evaluate the efficacy of olokizumab (OKZ) 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w) relative to placebo in subjects with moderately to severely active rheumatoid arthritis (RA) inadequately controlled by TNF-α inhibitor (TNFi) therapy.

Rheumatoid Arthritis

R-Pharm International, LLC368 participantsStarted Jan 2017

Phoenix, Arizona, United States • Hot Springs, Arkansas, United States • Covina, California, United States +113 more locations

Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

Find Trials by Condition in Denver

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

Impact of Fever Prevention in Brain Injured Patients

Evaluation of Topical Application of BMX-010 in Subjects With Acne Vulgaris.

Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.

Cannabidiol and Focus Study (CBD-Focus)

Subchondroplasty® Knee RCT

Immune Modulators for Treating COVID-19

Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

Low-Dose Ibuprofen in Improving Cognitive Impairment in Patients With Cancer

A Study Assessing the Safety and Effectiveness of IC2000 and SPY Fluorescence Imaging Systems (SPY-PHI) in the Visualization of Lymphatic Vessels and Identification of Lymph Nodes During Sentinel Lymph Node Biopsy in Subjects With Breast Cancer

Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity

A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

MyoVista wavECG Clinical Validation Study Versus Low e' on Echocardiogram

PV Loop and Pulmonary Hypertension

Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen

A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma

A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors

A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer